Effect of Teriparatide on Intertrochanteric Fractures Healing

Evaluation of the effect of the combination of Teriparatide and Calcium supplement in comparison with Calcium supplement alone on intertrochanteric fracture healing

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201121049452N1

Enrollment

Registered

2021-01-24

Start date

2019-01-21

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intertrochanteric Fractures.

Interventions

Intervention 1: Intervention group: Patients undergoing gamma nail surgery also receive Teriparatide(Cinnopar-Cinnagen company) 20 micrograms subcutaneously per day from the day of discharge for 3 mo

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: People over 50 years old with intertrochanteric fractures use Triaparatide for a period of 3 months after surgery Vitamin D with normal serum levels

Exclusion criteria

Exclusion criteria: Teriparatide is prescribed before surgery Teriparatide is prescribed for less than 3 months Unacceptable fracture reduction Multiple fractures Underlying conditions, or self-medication that affects bone repai Contralateral pelvic fractures Pathological fractures Any anti-osteoporosis medication (except calcium and vitamin d tablets) Deficiencies in medical records

Design outcomes

Primary

Measure	Time frame
Fracture healing time. Timepoint: Imaging at 2 and 4 weeks after surgery, then every 4 weeks until the fracture heals after taking teriparatide. Method of measurement: Radiological evaluation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Mehdi Omidian

Shahid Beheshti University of Medical Sciences

Behnamtarinn@gmail.com+98 21 8602 5210

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026